Antabio’s profile is featured in a double-page article of the June 2014 special issue on infectious diseases of Nature Biopharma Dealmakers.
The article describes the company’s history since its inception featuring some of its most innovative achievements, including the first successful round of crowdfunding applied to biotech start-up financing. The article also highlights the Wellcome Trust support to Antabio’s leading discovery program aimed at developing inhibitors of metallo beta-lactamases as well as the ongoing collaboration with UK-based Argenta to accelerate the optimization of Antabio’s proprietary Gram-Negative anti-infective leads.
